3-Aminophenyl-(4-pyridyl)-keton | 62246-96-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-Aminophenyl-(4-pyridyl)-keton
• 英文别名: (3-amino-phenyl)-pyridin-4-yl-methanone；(3-Aminophenyl)(pyridin-4-yl)methanone；(3-aminophenyl)-pyridin-4-ylmethanone
• CAS: 62246-96-2
• 化学式: C₁₂H₁₀N₂O
• mdl: MFCD06090938
• 分子量: 198.224
• InChiKey: LQORVTFJCCREQE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  56
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-Aminophenyl-(4-pyridyl)-keton 、 2-溴代-2-乙酰基萘 在 potassium carbonate 作用下， 以 乙酸乙酯 、 乙腈 为溶剂， 反应 72.5h， 生成
  参考文献：
  名称：

  Indolizine Derivatives as HIV-1 VIF-ElonginC Interaction Inhibitors

  摘要：

  Compound 1 (VEC‐5) was identified as a potent small‐molecular HIV‐1 viron infectivity factor inhibitor that targets the viron infectivity factor–ElonginC interaction. A structure–activity relationship study was carried out to develop compounds with improved efficacy against HIV‐1 and 49 indolizine derivatives of three categories were designed and synthesized. We found that five compounds exhibited promising anti‐HIV‐1 activity, and the most active compound 2g had an IC50 value of 11.0 μm. These results provide new information to develop highly potent small‐molecule HIV‐1 viron infectivity factor inhibitors.

  DOI：

  10.1111/cbdd.12119

文献信息

• 1H,3H-pyrrol[1,2-c]thiazole derivatives and pharmaceutical compositions
  申请人：Rhone-Poulenc Sante

  公开号：US04783472A1

  公开（公告）日：1988-11-08

  A compound of the general formula I; ##STR1## in which R is hydrogen or a halogen or an alkyl, alkyloxy, alkylthio, trifluoromethyl, amino, alkylamino, dialkylamino, hydroxy, cyano, carboxy, alkylsulphinyl, alkylsulphonyl, sulphamido, alkylsulphamido, dialkylsulphamido, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, phenylcarbamoyl, diphenylcarbamoyl, pyridylcarbamoyl, dipyridylcarbamoyl, benzyl, alkylcarbonyl, benzoyl, alkyloxycarbonyl, phenoxycarbonyl, alkylcarbonyloxy, benzoyloxy, alkylcarbonylamino, benzamido, phenyl, phenoxy or phenylthio group, X is oxygen or sulphur or an imino, alkylimino, phenylimino, benzylimino, sulphinyl, sulphonyl, carbonyl, carbonylmethylene, methylenecarbonyl, carbonylvinylene or vinylenecarbonyl group, or X represents a valency bond or a straight-chain alkylene group containing 1 to 4 carbon atoms and Ar is a phenyl, naphthyl, pyridyl, quinolinyl, isoquinolinyl, thienyl, benzothienyl, thieno[3,2-b]thien-2-yl or thieno[2,3-b]thien-2-yl group, it being possible for the group Ar to be unsubstituted or substituted with one or more halogen or alkyl, alkyloxy, alkylthio, trifluoromethyl, amino, alkylamino, dialkylamino, hydroxy, cyano, carboxy, alkylsulphinyl, alkylsulphonyl, sulphamido, alkylsulphamido, dialkylsulphamido, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, phenylcarbamoyl, diphenylcarbamoyl, pyridylcarbamoyl, dipyridylcarbamoyl, benzyl, alkylcarbonyl, benzoyl, alkyloxycarbonyl, phenoxycarbonyl, alkylcarbonyloxy, benzoyloxy, alkylcarbonylamino or benzamido group; each alkyl moiety containing 1 to 4 straight- or branched-chain carbon atoms; the compound being in separate enantiomeric form or mixtures thereof or a pharmaceutically acceptable salt thereof is useful in the treatment of all the pathological conditions in which PAF-acether may be directly or indirectly implicated.

  通式为I的化合物；##STR1## 其中R是氢或卤素或烷基，烷氧基，烷硫基，三氟甲基，氨基，烷基氨基，二烷基氨基，羟基，氰基，羧基，烷基磺酰基，烷基磺酰基，磺酰胺基，烷基磺酰胺基，二烷基磺酰胺基，氨基甲酰基，烷基氨甲酰基，二烷基氨甲酰基，苯基氨甲酰基，二苯基氨甲酰基，吡啶基氨甲酰基，二吡啶基氨甲酰基，苄基，烷基羰基，苯甲酰基，烷氧羰酰基，苯氧羰酰基，烷基羰酰氧基，苯甲酰氧基，烷基羰基氨基，苯甲酰胺基，苯基，苯氧基或苯硫基，X是氧或硫或亚胺基，烷基亚胺基，苯基亚胺基，苄基亚胺基，磺酰基，磺酰基，羰基，羰基亚甲基，羰基乙烯基或乙烯基羰基基团，或X表示价键或含有1到4个碳原子的直链烷基基团，Ar是苯基，萘基，吡啶基，喹啉基，异喹啉基，噻吩基，苯并噻吩基，噻吩[3,2-b]噻吩-2-基或噻吩[2,3-b]噻吩-2-基团，其中Ar基团可能是未取代或取代一个或多个卤素或烷基，烷氧基，烷硫基，三氟甲基，氨基，烷基氨基，二烷基氨基，羟基，氰基，羧基，烷基磺酰基，烷基磺酰基，磺酰胺基，烷基磺酰胺基，二烷基磺酰胺基，氨基甲酰基，烷基氨甲酰基，二烷基氨甲酰基，苯基氨甲酰基，二苯基氨甲酰基，吡啶基氨甲酰基，二吡啶基氨甲酰基，苄基，烷基羰基，苯甲酰基，烷氧羰酰基，苯氧羰酰基，烷基羰酰氧基，苯甲酰氧基，烷基羰基氨基，苯甲酰胺基或苯基氨基基团；每个烷基含有1到4个直链或支链碳原子；该化合物以分离的对映异构体形式或其混合物或其药学上可接受的盐形式在PAF-acether可能直接或间接涉及的所有病理情况的治疗中有用。
• US4783472A
  申请人：——

  公开号：US4783472A

  公开（公告）日：1988-11-08
• Indolizine Derivatives as HIV-1 VIF-ElonginC Interaction Inhibitors
  作者：Wenlin Huang、Tao Zuo、Xiao Luo、Hongwei Jin、Zhenming Liu、Zhenjun Yang、Xianghui Yu、Liangren Zhang、Lihe Zhang

  DOI：10.1111/cbdd.12119

  日期：2013.6

  Compound 1 (VEC‐5) was identified as a potent small‐molecular HIV‐1 viron infectivity factor inhibitor that targets the viron infectivity factor–ElonginC interaction. A structure–activity relationship study was carried out to develop compounds with improved efficacy against HIV‐1 and 49 indolizine derivatives of three categories were designed and synthesized. We found that five compounds exhibited promising anti‐HIV‐1 activity, and the most active compound 2g had an IC50 value of 11.0 μm. These results provide new information to develop highly potent small‐molecule HIV‐1 viron infectivity factor inhibitors.